Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Sterol Regulatory Element-Binding Protein 1 (SREBF1), a central regulator of lipid metabolism, has unclear pan-cancer roles and clinical implications. This study integrated various databases and functional experiments to systematically investigate the heterogeneous characteristics of SREBF1 across cancers. Pan-cancer analysis revealed significant upregulation of SREBF1 in multiple cancer types, including colorectal cancer (CRC). Survival analysis demonstrated that SREBF1 overexpression serves as an independent risk factor for poor prognosis in colorectal cancer patients. Focusing on CRC, functional studies revealed that SREBF1 drives tumor progression by enhancing cancer cell proliferation and migration, while its knockdown induces cell cycle arrest and apoptosis in HCT116 cells. Mechanistically, SREBF1 is implicated in lipid metabolic reprogramming and interacts with the tumor immune microenvironment, also with genetic alterations. This study highlights the regulatory role of SREBF1 in pan-cancer contexts and provides novel insights into its potential as a prognostic biomarker and therapeutic target, particularly in colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266389 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0327503 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Accounting for endoscopic screening in colorectal cancer risk models.
Cancer Epidemiol Biomarkers Prev
September 2025
Brigham and Women's Hospital, Boston, MA, United States.
Background: Colorectal cancer (CRC) risk models routinely adjust for endoscopic screening because of a) possible confounding with other risk factors and b) possible alteration of natural history of the disease due to adenoma detection and removal.
Methods: In this study, we defined a subject as screen-covered (SC) if a colonoscopy was performed in the past 10 years, and not screen-covered (NSC) otherwise. We created CRC risk models separately for SC and NSC subjects (HRSC, HRNSC) and then obtained a screening-coverage adjusted HR estimate (HRfull) based on a weighted average of ln(HRSC) and ln(HRNSC) with weight equal to the proportion of SC person-time in the NHS population.
Stanford Type A Aortic Dissection During Adjuvant Capecitabine Chemotherapy for Colorectal Cancer.
JACC Case Rep
September 2025
Department of Cardiovascular Surgery, Nagoya Heart Center, Nagoya, Japan.
Background: Capecitabine, an oral prodrug of 5-fluorouracil, is widely used for gastrointestinal malignancies. While its coronary toxicity is well documented, large-vessel complications such as aortic dissection are rarely reported.
Case Summary: We present a 65-year-old man with colorectal cancer who developed Stanford type A aortic dissection 3 days after initiating adjuvant capecitabine therapy.
Challenges of decision-making after treatment with immunotherapy in metastatic deficient DNA mismatch repair/microsatellite unstable colorectal cancer.
Br J Surg
September 2025
Department of Digestive Surgery, CARPEM Comprehensive Cancer Centre, Georges-Pompidou European Hospital, AP-HP, Université Paris-Cité, Paris, France.
The effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer.
Rep Pract Oncol Radiother
August 2025
Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, Poznan, Poland.
Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer.
View Article and Find Full Text PDFNatural product Erianin: mitigating FOLFOX toxicity and enhancing against colorectal cancer.
Front Chem
August 2025
Guangzhou Key Laboratory of Formula-Pattern Research Center, School of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Jinan University, Guangzhou, China.
Introduction: Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. The FOLFOX regimen (oxaliplatin + calcium folinate + 5-fluorouracil) serves as the primary treatment for advanced CRC clinically, yet its application is significantly limited by substantial toxic side effects. Erianin, a natural compound from Chinese medicine Lindl, demonstrates significant potential in both tumor growth inhibition and chemotherapy toxicity reduction.
View Article and Find Full Text PDF